Utilidad en la prevención, tratamiento y pronóstico de la medicina de precisión en oncología

Usefulness of precision medicine in improving prevention, treatment and prognosis in oncology

Contenido principal del artículo

Eduardo Reyna Villasmil

Resumen

Introducción: El desarrollo de la genética en las últimas décadas ha abierto una nueva era. La medicina de precisión ha aprovechado estos avances para desempeñar un papel cada vez más importante en la prevención, el diagnóstico y tratamiento del cáncer. Objetivo: evaluar la utilidad de la medicina de precisión en la prevención, tratamiento y pronóstico en oncología. Discusión: los estudios de la carcinogénesis han llevado al descubrimiento de eventos cruciales en el desarrollo de neoplasias malignas, identificando subtipos distintos de varios tumores comunes desde el punto de vista molecular. Con ello se ha logrado una mejor caracterización de los tumores que antes solo dependía de los hallazgos histopatológicos y el desarrollo de nuevos fármacos, generando cambios en el paradigma de la atención del paciente oncológico. La identificación de mutaciones que pueden predisponer al cáncer como las mutaciones BRCA en el cáncer de mama, ha facilitado el cribado para identificar pacientes para ayudar a tomar decisiones y modificar el riesgo. Conclusiones: la eficacia de varias terapias antitumorales sugiere el inicio de una era en la que las acciones preventivas y decisiones clínicas estarán basadas en el perfil de anomalías genéticas del tumor, mejorando el pronóstico y la calidad de vida de los pacientes. Esto conducirá a que cada vez sea más frecuente este tipo de tratamiento de precisión basado en el perfil de cambios genéticos.

Palabras clave:

Descargas

Los datos de descargas todavía no están disponibles.

Detalles del artículo

Referencias

Santos-Cortez RLP, Bhutta MF, Earl JP, Hafrén L, Jennings M, Mell JC, Pichichero ME, Ryan AF, Tateossian H, Ehrlich GD. Panel 3: Genomics, precision medicine and targeted therapies. Int J Pediatr Otorhinolaryngol. 2020;130 Suppl 1(Suppl 1):109835. doi: 10.1016/j.ijporl.2019.109835. DOI: https://doi.org/10.1016/j.ijporl.2019.109835

Amekyeh H, Tarlochan F, Billa N. Practicality of 3D printed personalized medicines in therapeutics. Front Pharmacol. 2021;12:646836. doi: 10.3389/fphar.2021.646836. DOI: https://doi.org/10.3389/fphar.2021.646836

Hebar A, Valent P, Selzer E. The impact of molecular targets in cancer drug development: major hurdles and future strategies. Expert Rev Clin Pharmacol. 2013;6(1):23-34. doi: 10.1586/ecp.12.71. DOI: https://doi.org/10.1586/ecp.12.71

Yu Z, Song M, Chouchane L, Ma X. Functional genomic analysis of breast cancer metastasis: implications for diagnosis and therapy. Cancers (Basel). 2021;13(13):3276. doi: 10.3390/cancers13133276. DOI: https://doi.org/10.3390/cancers13133276

Huebner T, Scholl C, Steffens M. Cytogenetic and biochemical genetic techniques for personalized drug therapy in Europe. Diagnostics (Basel). 2021;11(7):1169. doi: 10.3390/diagnostics11071169. DOI: https://doi.org/10.3390/diagnostics11071169

Norrie JL, Nityanandam A, Lai K, Chen X, Wilson M, Stewart E, Griffiths L, Jin H, Wu G, Orr B, Tran Q, Allen S, Reilly C, Zhou X, Zhang J, Newman K, Johnson D, Brennan R, Dyer MA. Retinoblastoma from human stem cell-derived retinal organoids. Nat Commun. 2021;12(1):4535. doi: 10.1038/s41467-021-24781-7. DOI: https://doi.org/10.1038/s41467-021-24781-7

Heck JE, Huang X, Calkins KL, Sun Y, Olsen J, Ritz B, Hansen J. Phototherapy and childhood cancer: Shared risk factors. Int J Cancer. 2020;146(7):2059-2062. doi: 10.1002/ijc.32701. DOI: https://doi.org/10.1002/ijc.32701

Houlston R. Identification of low-penetrance alleles associated with colon cancer risk. Med Sci (Paris). 2009;25 Spec No 1:39-41. doi: 10.1051/medsci/2009251s39. DOI: https://doi.org/10.1051/medsci/2009251s39

Capellini A, Williams M, Onel K, Huang KL. The functional hallmarks of cancer predisposition genes. Cancer Manag Res. 2021;13:4351-4357. doi: 10.2147/CMAR.S311548. DOI: https://doi.org/10.2147/CMAR.S311548

Bharucha PP, Chiu KE, François FM, Scott JL, Khorjekar GR, Tirada NP. Genetic testing and screening recommendations for patients with hereditary breast cancer. Radiographics. 2020;40(4):913-936. doi: 10.1148/rg.2020190181. DOI: https://doi.org/10.1148/rg.2020190181

Howard TP, Vazquez F, Tsherniak A, Hong AL, Rinne M, Aguirre AJ, Boehm JS, Hahn WC. Functional genomic characterization of cancer genomes. Cold Spring Harb Symp Quant Biol. 2016;81:237-246. doi: 10.1101/sqb.2016.81.031070. DOI: https://doi.org/10.1101/sqb.2016.81.031070

Kutkowska J, Strzadala L, Rapak A. Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells. Cancer Sci. 2017;108(11):2265-2272. doi: 10.1111/cas.13386. DOI: https://doi.org/10.1111/cas.13386

Chen L, Liu S, Tao Y. Regulating tumor suppressor genes: post-translational modifications. Signal Transduct Target Ther. 2020;5(1):90. doi: 10.1038/s41392-020-0196-9. DOI: https://doi.org/10.1038/s41392-020-0196-9

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. doi: 10.1016/j.cell.2011.02.013. DOI: https://doi.org/10.1016/j.cell.2011.02.013

Gisselsson D, Egnell R. Cancer - An insurgency of clones. Trends Cancer. 2017;3(2):73-75. doi: 10.1016/j.trecan.2016.11.010. DOI: https://doi.org/10.1016/j.trecan.2016.11.010

Soltanian S, Matin MM. Cancer stem cells and cancer therapy. Tumour Biol. 2011;32(3):425-40. doi: 10.1007/s13277-011-0155-8. DOI: https://doi.org/10.1007/s13277-011-0155-8

Beijnen JH, Schellens JH. Personalized medicine in oncology: a personal view with myths and facts. Curr Clin Pharmacol. 2010;5(3):141-7. doi: 10.2174/157488410791498789. DOI: https://doi.org/10.2174/157488410791498789

Vishwakarma R, McManus KJ. Chromosome instability; Implications in cancer development, progression, and clinical outcomes. Cancers (Basel). 2020;12(4):824. doi: 10.3390/cancers12040824. DOI: https://doi.org/10.3390/cancers12040824

Mainor CB, Isaacs C. Risk Management for BRCA1/BRCA2 mutation carriers without and with breast cancer. Curr Breast Cancer Rep. 2020;12(2):66-74. doi: 10.1007/s12609-019-00350-2. DOI: https://doi.org/10.1007/s12609-019-00350-2

Lewis KM. Identifying hereditary cancer: genetic counseling and cancer risk assessment. Curr Probl Cancer. 2014;38(6):216-25. doi: 10.1016/j.currproblcancer.2014.10.002. DOI: https://doi.org/10.1016/j.currproblcancer.2014.10.002

McClellan J, King MC. Genetic heterogeneity in human disease. Cell. 2010;141(2):210-7. doi: 10.1016/j.cell.2010.03.032. DOI: https://doi.org/10.1016/j.cell.2010.03.032

Tian H, Gao Z, Li H, Zhang B, Wang G, Zhang Q, Pei D, Zheng J. DNA damage response--a double-edged sword in cancer prevention and cancer therapy. Cancer Lett. 2015;358(1):8-16. doi: 10.1016/j.canlet.2014.12.038. DOI: https://doi.org/10.1016/j.canlet.2014.12.038

Szczerba E, Kamińska K, Mierzwa T, Misiek M, Kowalewski J, Lewandowska MA. BRCA1/2 mutation detection in the tumor tissue from selected polish patients with breast cancer using Next Generation Sequencing. Genes (Basel). 2021;12(4):519. doi: 10.3390/genes12040519. DOI: https://doi.org/10.3390/genes12040519

Landrum MJ, Chitipiralla S, Brown GR, Chen C, Gu B, Hart J, Hoffman D, Jang W, Kaur K, Liu C, Lyoshin V, Maddipatla Z, Maiti R, Mitchell J, O'Leary N, Riley GR, Shi W, Zhou G, Schneider V, Maglott D, Holmes JB, Kattman BL. ClinVar: improvements to accessing data. Nucleic Acids Res. 2020;48(D1):D835-D844. doi: 10.1093/nar/gkz972. DOI: https://doi.org/10.1093/nar/gkz972

Dumbrava EI, Meric-Bernstam F. Personalized cancer therapy-leveraging a knowledge base for clinical decision-making. Cold Spring Harb Mol Case Stud. 2018;4(2):a001578. doi: 10.1101/mcs.a001578. DOI: https://doi.org/10.1101/mcs.a001578

Hughes E, Tshiaba P, Wagner S, Judkins T, Rosenthal E, Roa B, Gallagher S, Meek S, Dalton K, Hedegard W, Adami CA, Grear DF, Domchek SM, Garber J, Lancaster JM, Weitzel JN, Kurian AW, Lanchbury JS, Gutin A, Robson ME. Integrating clinical and polygenic factors to predict breast cancer risk in women undergoing genetic testing. JCO Precis Oncol. 2021;5:PO.20.00246. doi: 10.1200/PO.20.00246. DOI: https://doi.org/10.1200/PO.20.00246

Qiu J, Xu J, Zhang K, Gu W, Nie L, Wang G, Luo Y. Refining cancer management using integrated liquid biopsy. Theranostics. 2020;10(5):2374-2384. doi: 10.7150/thno.40677. DOI: https://doi.org/10.7150/thno.40677

Kristensen BW, Priesterbach-Ackley LP, Petersen JK, Wesseling P. Molecular pathology of tumors of the central nervous system. Ann Oncol. 2019;30(8):1265-1278. doi: 10.1093/annonc/mdz164. DOI: https://doi.org/10.1093/annonc/mdz164

Elkamhawy A, Lu Q, Nada H, Woo J, Quan G, Lee K. The Journey of DDR1 and DDR2 Kinase Inhibitors as Rising Stars in the Fight Against Cancer. Int J Mol Sci. 2021;22(12):6535. doi: 10.3390/ijms22126535. DOI: https://doi.org/10.3390/ijms22126535

Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O'Neill KM, Balter ML, Fritz ZR, Androulakis IP, Schloss RS, Yarmush ML. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci). 2018;6(3-4):79-100. doi: 10.1142/S2339547818300020. DOI: https://doi.org/10.1142/S2339547818300020

Helgadottir H, Rocha Trocoli Drakensjö I, Girnita A. Personalized medicine in malignant melanoma: Towards patient tailored treatment. Front Oncol. 2018;8:202. doi: 10.3389/fonc.2018.00202. DOI: https://doi.org/10.3389/fonc.2018.00202

Afrăsânie VA, Marinca MV, Alexa-Stratulat T, Gafton B, Păduraru M, Adavidoaiei AM, Miron L, Rusu C. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician. Radiol Oncol. 2019;53(3):265-274. doi: 10.2478/raon-2019-0033. DOI: https://doi.org/10.2478/raon-2019-0033

von Manstein V, Yang CM, Richter D, Delis N, Vafaizadeh V, Groner B. Resistance of cancer cells to targeted therapies through the activation of compensating signaling loops. Curr Signal Transduct Ther. 2013;8(3):193-202. doi: 10.2174/1574362409666140206221931. DOI: https://doi.org/10.2174/1574362409666140206221931

Vieira AF, Schmitt F. An update on breast cancer multigene prognostic tests-emergent clinical biomarkers. Front Med (Lausanne). 2018;5:248. doi: 10.3389/fmed.2018.00248. DOI: https://doi.org/10.3389/fmed.2018.00248

Schildgen V, Warm M, Brockmann M, Schildgen O. Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT2-Profiler Multiplex RT-PCR. Sci Rep. 2019;9(1):20266. doi: 10.1038/s41598-019-56910-0. DOI: https://doi.org/10.1038/s41598-019-56910-0

Citado por